Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0S8HD
|
||||
| Former ID |
DIB015911
|
||||
| Drug Name |
PEP-223/CoVaccine HT
|
||||
| Synonyms |
Prostate cancer vaccine, Pepscan/Novartis; Prostate cancer vaccine, Pepscan/PowderJect; Prostate cancer vaccine(anti-GnRH, TDK), Pepscan
|
||||
| Drug Type |
Vaccine
|
||||
| Indication | Prostate cancer [ICD9: 185; ICD10:C61] | Phase 1/2 | [1] | ||
| Company |
Pepscan Systems BV
|
||||
| Target and Pathway | |||||
| Target(s) | Gonadotropin-releasing hormone receptor | Target Info | [2] | ||
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| GnRH signaling pathway | |||||
| NetPath Pathway | IL1 Signaling Pathway | ||||
| IL2 Signaling Pathway | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Reactome | Hormone ligand-binding receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00895466) Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients. U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 256). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.